Novel Clinical Trials and Approaches in the Management of Glioblastoma

IF 4.7 2区医学 Q1 ONCOLOGY Current Oncology Reports Pub Date : 2024-03-28 DOI:10.1007/s11912-024-01519-4

Allison R. Valerius, Lauren M. Webb, Ugur Sener

{"title":"Novel Clinical Trials and Approaches in the Management of Glioblastoma","authors":"Allison R. Valerius, Lauren M. Webb, Ugur Sener","doi":"10.1007/s11912-024-01519-4","DOIUrl":null,"url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of Review</h3><p>The purpose of this review is to discuss a wide variety of novel therapies recently studied or actively undergoing study in patients with glioblastoma. This review also discusses current and future strategies for improving clinical trial design in patients with glioblastoma to maximize efficacy in discovering effective treatments.</p><h3 data-test=\"abstract-sub-heading\">Recent Findings</h3><p>Over the years, there has been significant expansion in therapy modalities studied in patients with glioblastoma. These therapies include, but are not limited to, targeted molecular therapies, DNA repair pathway targeted therapies, immunotherapies, vaccine therapies, and surgically targeted radiotherapies.</p><h3 data-test=\"abstract-sub-heading\">Summary</h3><p>Glioblastoma is the most common malignant primary brain tumor in adults and unfortunately remains with poor overall survival following the current standard of care. Given the dismal prognosis, significant clinical and research efforts are ongoing with the goal of improving patient outcomes and enhancing quality and quantity of life utilizing a wide variety of novel therapies.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":null,"pages":null},"PeriodicalIF":4.7000,"publicationDate":"2024-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Oncology Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11912-024-01519-4","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of Review

The purpose of this review is to discuss a wide variety of novel therapies recently studied or actively undergoing study in patients with glioblastoma. This review also discusses current and future strategies for improving clinical trial design in patients with glioblastoma to maximize efficacy in discovering effective treatments.

Recent Findings

Over the years, there has been significant expansion in therapy modalities studied in patients with glioblastoma. These therapies include, but are not limited to, targeted molecular therapies, DNA repair pathway targeted therapies, immunotherapies, vaccine therapies, and surgically targeted radiotherapies.

Summary

Glioblastoma is the most common malignant primary brain tumor in adults and unfortunately remains with poor overall survival following the current standard of care. Given the dismal prognosis, significant clinical and research efforts are ongoing with the goal of improving patient outcomes and enhancing quality and quantity of life utilizing a wide variety of novel therapies.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

治疗胶质母细胞瘤的新型临床试验和方法

综述目的本综述旨在讨论最近对胶质母细胞瘤患者进行研究或正在进行研究的各种新型疗法。本综述还讨论了改进胶质母细胞瘤患者临床试验设计的当前和未来策略，以最大限度地提高发现有效治疗方法的效率。这些疗法包括但不限于分子靶向疗法、DNA 修复通路靶向疗法、免疫疗法、疫苗疗法和手术靶向放射疗法。摘要胶质母细胞瘤是成人中最常见的恶性原发性脑肿瘤，不幸的是，目前的标准治疗方法的总体生存率仍然很低。鉴于预后不佳，目前正在开展大量临床和研究工作，目的是利用各种新型疗法改善患者预后，提高生活质量和数量。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Oncology Reports ONCOLOGY-

CiteScore

8.50

自引率

0.00%

发文量

187

审稿时长

6-12 weeks

期刊介绍： This journal aims to review the most important, recently published clinical findings in the field of oncology. By providing clear, insightful, balanced contributions by international experts, the journal intends to serve all those involved in the care of those affected by cancer. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as cancer prevention, leukemia, melanoma, neuro-oncology, and palliative medicine. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.